Medication stops the attack, but physical therapy rebuilds the strength. Learn how specialized neuro-PT helps ‘re-map’ movements and prevent permanent damage in chronic inflammatory demyelinating ...

Treatment for chronic inflammatory demyelinating polyneuropathy (CIDP), a chronic autoimmune condition that affects the protective layer around your nerves, usually starts with one of three options.

NVG-2089 is a recombinant Fc fusion protein designed to replicate key immunomodulatory functions of IVIg with greater consistency, scalability, and patient convenience Phase 1 data show NVG-2089 was ...

As many as four percent of the world’s population lives with an autoimmune disease, in which the immune system fails to distinguish between ‘self’ and ‘non-self’ and mistakenly attacks the body, ...

Please provide your email address to receive an email when new articles are posted on . Gammagard Liquid is an immune globulin infusion (human) 10% solution. It is the only IV-based immunoglobulin ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and ...

argenx has released preliminary results from the ADHERE trial, which tested VYVGART Hytrulo on adults with chronic inflammatory demyelinating polyneuropathy (CIDP), where the trial results were ...

(RTTNews) - Takeda Pharmaceutical Co. Ltd. (TAK) announced Tuesday favorable long-term data from the Phase 3 ADVANCE-CIDP 3 clinical trial of HYQVIA in Patients with Chronic Inflammatory Demyelinating ...

This week, we are going to continue down the road of autoimmune peripheral nerve conditions to discuss two that we have touched on in the past—Guillain-Barré Syndrome and CIDP (chronic inflammatory ...

Even in remission, chronic inflammatory demyelinating polyneuropathy (CIDP) fatigue can be draining. Learn how to use the spoon theory, pacing strategies, and ergonomic tools to manage your "energy ...